Should the Dermatological Assessment of Patients with Inflammatory Bowel Disease Become Standard during Qualifications for Biological Treatment? A Retrospective, Single-Center Experience from a Tertiary Center
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Patients
2.2. Outcomes
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Łodyga, M.; Eder, P.; Gawron-Kiszka, M.; Dobrowolska, A.; Gonciarz, M.; Hartleb, M.; Kłopocka, M.; Małecka-Wojciesko, E.; Radwan, P.; Reguła, J.; et al. Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Prz. Gastroenterol. 2021, 16, 257–296. [Google Scholar] [CrossRef]
- Eder, P.; Łodyga, M.; Gawron-Kiszka, M.; Dobrowolska, A.; Gonciarz, M.; Hartleb, M.; Kłopocka, M.; Małecka-Wojciesko, E.; Radwan, P.; Reguła, J.; et al. Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Prz. Gastroenterol. 2023, 18, 1–42. [Google Scholar] [CrossRef] [PubMed]
- Raine, T.; Bonovas, S.; Burisch, J.; Kucharzik, T.; Adamina, M.; Annese, V.; Bachmann, O.; Bettenworth, D.; Chaparro, M.; Czuber-Dochan, W.; et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J. Crohn’s Colitis 2022, 16, 2–17. [Google Scholar] [CrossRef] [PubMed]
- Torres, J.; Bonovas, S.; Doherty, G.; Kucharzik, T.; Gisbert, J.P.; Raine, T.; Adamina, M.; Armuzzi, A.; Bachmann, O.; Bager, P.; et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J. Crohn’s Colitis 2020, 14, 4–22. [Google Scholar] [CrossRef]
- Gordon, H.; Biancone, L.; Fiorino, G.; Katsanos, K.H.; Kopylov, U.; Al Sulais, E.; Axelrad, J.E.; Balendran, K.; Burisch, J.; de Ridder, L.; et al. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. J. Crohn’s Colitis 2023, 17, 827–854. [Google Scholar] [CrossRef] [PubMed]
- Bousis, D.; Verras, G.I.; Bouchagier, K.; Antzoulas, A.; Panagiotopoulos, I.; Katinioti, A.; Kehagias, D.; Kaplanis, C.; Kotis, K.; Anagnostopoulos, C.N.; et al. The role of deep learning in diagnosing colorectal cancer. Prz. Gastroenterol. 2023, 18, 266–273. [Google Scholar] [CrossRef]
- Chlorogiannis, D.D.; Verras, G.I.; Tzelepi, V.; Chlorogiannis, A.; Apostolos, A.; Kotis, K.; Anagnostopoulos, C.N.; Antzoulas, A.; Davakis, S.; Vailas, M.; et al. Tissue classification and diagnosis of colorectal cancer histopathology images using deep learning algorithms. Is the time ripe for clinical practice implementation? Prz. Gastroenterol. 2023, 18, 353–367. [Google Scholar] [CrossRef]
- Lewandowski, K.; Kaniewska, M.; Więcek, M.; Panufnik, P.; Tulewicz-Marti, E.; Głuszek-Osuch, M.; Ciechanowicz, P.; Walecka, I.; Rydzewska, G. Dermal lesions associated with anti-tumor necrosis factor-α therapy in patients with inflammatory bowel disease: Findings from an inflammatory bowel disease tertiary center in Poland. Pol. Arch. Intern. Med. 2024, 134, 16789. [Google Scholar]
- Cushing, K.C.; Du, X.; Chen, Y.; Stetson, L.C.; Kuppa, A.; Chen, V.L.; Kahlenberg, J.M.; Gudjonsson, J.E.; Vanderwerff, B.; Higgins, P.D.R.; et al. Inflammatory Bowel Disease Risk Variants Are Associated with an Increased Risk of Skin Cancer. Inflamm. Bowel Dis. 2022, 28, 1667–1676. [Google Scholar] [CrossRef]
- Kucharzik, T.; Ellul, P.; Greuter, T.; Rahier, J.F.; Verstockt, B.; Abreu, C.; Albuquerque, A.; Allocca, M.; Esteve, M.; Farraye, F.A.; et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J. Crohn’s Colitis 2021, 15, 879–913. [Google Scholar] [CrossRef]
- Sebastian, S.; Neilaj, S. Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment? Ther. Adv. Gastroenterol. 2019, 12, 1756284818817293. [Google Scholar] [CrossRef] [PubMed]
- Russomanno, K.; Abdel Azim, S.; Patel, V.A. Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives. Clin. Cosmet. Investig. Dermatol. 2023, 16, 1025–1045. [Google Scholar] [CrossRef] [PubMed]
- Farraye, F.A.; Melmed, G.Y.; Lichtenstein, G.R.; Kane, S.V. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am. J. Gastroenterol. 2017, 112, 241–258. [Google Scholar] [CrossRef] [PubMed]
- Johnson, M.M.; Leachman, S.A.; Aspinwall, L.G.; Cranmer, L.D.; Curiel-Lewandrowski, C.; Sondak, V.K.; Stemwedel, C.E.; Swetter, S.M.; Vetto, J.; Bowles, T.; et al. Skin cancer screening: Recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag. 2017, 4, 13–37. [Google Scholar] [CrossRef]
- Collins, L.; Asfour, L.; Stephany, M.; Lear, J.T.; Stasko, T. Management of Non-melanoma Skin Cancer in Transplant Recipients. Clin. Oncol. 2019, 31, 779–788. [Google Scholar] [CrossRef]
- Lam, K.; Coomes, E.A.; Nantel-Battista, M.; Kitchen, J.; Chan, A.W. Skin cancer screening after solid organ transplantation: Survey of practices in Canada. Am. J. Transplant. 2019, 19, 1792–1797. [Google Scholar] [CrossRef]
- Huang, S.Z.; Liu, Z.C.; Liao, W.X.; Wei, J.X.; Huang, X.W.; Yang, C.; Xia, Y.H.; Li, L.; Ye, C.; Dai, S.X. Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2019, 34, 507–516. [Google Scholar] [CrossRef]
- Singh, S.; Nagpal, S.J.; Murad, M.H.; Yadav, S.; Kane, S.V.; Pardi, D.S.; Talwalkar, J.A.; Loftus, E.V. Inflammatory bowel disease is associated with an increased risk of melanoma: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2014, 12, 210–218. [Google Scholar] [CrossRef]
- Singh, H.; Nugent, Z.; Demers, A.A.; Bernstein, C.N. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011, 141, 1612–1620. [Google Scholar] [CrossRef]
- Malik, T.F.; Aurelio, D.M. Extraintestinal Manifestations of Inflammatory Bowel Disease. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2023. [Google Scholar]
- Martins, L.M.S.; Perez, M.M.; Pereira, C.A.; Costa, F.R.C.; Dias, M.S.; Tostes, R.C.; Ramos, S.G.; de Zoete, M.R.; Ryffel, B.; Silva, J.S.; et al. Interleukin-23 promotes intestinal T helper type17 immunity and ameliorates obesity-associated metabolic syndrome in a murine high-fat diet model. Immunology 2018, 154, 624–636. [Google Scholar] [CrossRef]
- Schäffler, H.; Blattmann, T.; Findeisen, A.; Meinel, F.G.; Meyer-Bahlburg, A.; Lamprecht, G.; Steinmüller-Magin, L.; Trauzeddel, R.; Emmert, S. PAPA-Syndrom mit Morbus Crohn und primär sklerosierender Cholangitis/Autoimmunhepatitis-Overlap-Syndrom [PAPA syndrome with Crohn’s disease and primary sclerosing cholangitis/autoimmune hepatitis overlap syndrome]. Hautarzt 2019, 70, 116–122. [Google Scholar] [CrossRef] [PubMed]
- Weizman, A.V.; Sharma, R.; Afzal, N.M.; Xu, W.; Walsh, S.; Stempak, J.M.; Nguyen, G.C.; Croitoru, K.; Steinhart, A.H.; Silverberg, M.S. Stricturing and Fistulizing Crohn’s Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease. Dig. Dis. Sci. 2018, 63, 2430–2438. [Google Scholar] [CrossRef]
- Patil, S.A.; Cross, R.K. More Skin in the Game: Screening for Skin Cancer in IBD Patients. Dig. Dis. Sci. 2018, 63, 2497–2499. [Google Scholar] [CrossRef] [PubMed]
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 2018, 68, 7–30. [Google Scholar] [CrossRef]
- Aitken, J.F.; Elwood, M.; Baade, P.D.; Youl, P.; English, D. Clinical whole-body skin examination reduces the incidence of thick melanomas. Int. J. Cancer 2010, 126, 450–458. [Google Scholar] [CrossRef] [PubMed]
- Wernli, K.J.; Henrikson, N.B.; Morrison, C.C.; Nguyen, M.; Pocobelli, G.; Whitlock, E.P. Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force; Report No.: 14-05210-EF-1; Agency for Healthcare Research and Quality (US): Rockville, MD, USA, 2016.
- Lemaitre, M.; Kirchgesner, J.; Rudnichi, A.; Carrat, F.; Zureik, M.; Carbonnel, F.; Dray-Spira, R. Association between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients with Inflammatory Bowel Disease. JAMA 2017, 318, 1679–1686. [Google Scholar] [CrossRef]
- Glazer, A.M.; Rigel, D.S. Analysis of Trends in Geographic Distribution of US Dermatology Workforce Density. JAMA Dermatol. 2017, 153, 472–473. [Google Scholar] [CrossRef]
- Finnane, A.; Dallest, K.; Janda, M.; Soyer, H.P. Teledermatology for the Diagnosis and Management of Skin Cancer: A Systematic Review. JAMA Dermatol. 2017, 153, 319–327. [Google Scholar] [CrossRef]
- Hamidi, R.; Peng, D.; Cockburn, M. Efficacy of skin self-examination for the early detection of melanoma. Int. J. Dermatol. 2010, 49, 126–134. [Google Scholar] [CrossRef]
- Trovato, E.; Dragotto, M.; Capalbo, E.; Cartocci, A.; Rubegni, P.; Calabrese, L. Risk of Skin Cancer in Patients with Psoriasis: Single-Center Retrospective Study Comparing Anti-TNFα and Phototherapy. J. Clin. Med. 2024, 13, 2452. [Google Scholar] [CrossRef]
Variable | n = 805 |
---|---|
Age, years, mean ± SD | 36.84 ± 12.49 |
Gender | |
Female | 348 (43.2) |
Male | 457 (56.8) |
BMI, kg/m2, mean ± SD | 23.73 ± 3.51 |
IBD | |
Ulcerative colitis | 196 (24.3) |
Crohn’s disease | 609 (75.7) |
Crohn’s disease, location | |
Small intestine | 76 (9.4) |
Large intestine | 48 (6.0) |
Ileocecal | 510 (63.4) |
Ulcerative colitis, location | |
Pancolitis | 183 (22.7) |
Left-sided | 13 (1.6) |
Proctitis | 22 (2.7) |
Steroids | |
Dependent | 740 (91.9) |
Resistant | 65 (8.1) |
5-ASA | 244 (30.3) |
Steroids | 499 (61.9) |
Thiopurine | 688 (85.5) |
Dermal lesions, any | 125 (15.5) |
Erythema nodosum | 21 (2.6) |
Pyoderma gangrenosum | 17 (2.1) |
Psoriasis | 9 (1.1) |
Hidradenitis suppurativa | 15 (1.9) |
Vitiligo | 5 (0.6) |
Phlebitis | 1 (0.1) |
Erythema multiforme | 2 (0.2) |
Urticaria | 11 (1.4) |
Xerosis and eczema | 44 (5.5) |
Cutaneous infections | 0 (0.0) |
Psorasiform reactions | 0 (0.0) |
Cutaneous malignancies | 9 (1.1) |
Lupus-like symptoms | 0 (0.0) |
Vasculitis | 0 (0.0) |
Alopecia areata/totalis and/or vitiligo | 2 (0.2) |
Regular dermatological visits | 92 (13.4) * |
Variable | Patients with Dermal Lesions (n = 125) | Patients without Dermal Lesions (n = 680) | MD/Cramer’s V (95% CI) | p-Value |
---|---|---|---|---|
Age, years, mean ± SD | 37.45 ± 12.03 | 36.73 ± 12.57 | 0.72 (−1.67; 3.10) | 0.555 |
Gender | ||||
Female | 44 (35.2) | 304 (44.7) | 0.07 (0.01; 0.13) | 0.061 |
Male | 81 (64.8) | 376 (55.3) | ||
BMI, kg/m2, median (IQR) | 24.81 (22.13; 26.57) | 23.58 (20.81; 26.03) | 1.23 (0.32; 1.65) | 0.004 |
IBD | ||||
Ulcerative colitis | 29 (23.2) | 167 (24.6) | 0.01 (0.00; 0.08) | 0.832 |
Crohn’s disease | 96 (76.8) | 513 (75.4) | ||
Crohn’s disease, location | ||||
Small intestine | 13 (10.4) | 63 (9.3) | 0.01 (0.00; 0.09) | 0.816 |
Large intestine | 11 (8.8) | 37 (5.4) | 0.05 (0.00; 0.14) | 0.211 |
Ileocecal | 79 (63.2) | 431 (63.4) | 0.00 (0.00; 0.08) | >0.999 |
Ulcerative colitis, location | ||||
Pancolitis | 25 (20.0) | 158 (23.2) | 0.03 (0.00; 0.09) | 0.498 |
Left-sided | 4 (3.2) | 9 (1.3) | 0.05 (0.00; 0.15) | 0.128 |
Proctitis | 3 (2.4) | 19 (2.8) | 0.01 (0.00; 0.07) | >0.999 |
Steroids | ||||
Dependent | 108 (86.4) | 632 (92.9) | 0.09 (0.01; 0.17) | 0.022 |
Resistant | 17 (13.6) | 48 (7.1) | ||
5-ASA | 35 (28.0) | 209 (30.7) | 0.02 (0.00; 0.09) | 0.613 |
Steroids | 68 (54.4) | 431 (63,3) | 0.07 (0.01; 0.14) | 0.072 |
Thiopurine | 113 (90.4) | 575 (84.6) | 0.06 (0.01; 0.12) | 0.118 |
Regular dermatological visits | 18 (14.4) | 74 (10.9) | 0.04 (0.00; 0.12) | 0.326 |
Variable | Multivariable Logistic Regression | ||||
---|---|---|---|---|---|
Coefficient | SE | OR | 95% CI | p | |
BMI, kg/m2 | 0.07 | 0.03 | 1.08 | 1.02–1.14 | 0.007 |
Crohn’s disease, location | |||||
Large intestine | 0.68 | 0.36 | 1.97 | 0.92–3.90 | 0.063 |
Ulcerative colitis, location | |||||
Left-sided | 1.11 | 0.62 | 3.04 | 0.80–9.74 | 0.072 |
Thiopurine | 0.56 | 0.33 | 1.74 | 0.95–3.47 | 0.089 |
Steroids, dependent (vs. resistant) | −0.81 | 0.31 | 0.45 | 0.25–0.83 | 0.008 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lewandowski, K.; Kaniewska, M.; Tulewicz-Marti, E.; Głuszek-Osuch, M.; Ciechanowicz, P.; Walecka, I.; Rydzewska, G. Should the Dermatological Assessment of Patients with Inflammatory Bowel Disease Become Standard during Qualifications for Biological Treatment? A Retrospective, Single-Center Experience from a Tertiary Center. J. Clin. Med. 2024, 13, 5213. https://doi.org/10.3390/jcm13175213
Lewandowski K, Kaniewska M, Tulewicz-Marti E, Głuszek-Osuch M, Ciechanowicz P, Walecka I, Rydzewska G. Should the Dermatological Assessment of Patients with Inflammatory Bowel Disease Become Standard during Qualifications for Biological Treatment? A Retrospective, Single-Center Experience from a Tertiary Center. Journal of Clinical Medicine. 2024; 13(17):5213. https://doi.org/10.3390/jcm13175213
Chicago/Turabian StyleLewandowski, Konrad, Magdalena Kaniewska, Edyta Tulewicz-Marti, Martyna Głuszek-Osuch, Piotr Ciechanowicz, Irena Walecka, and Grażyna Rydzewska. 2024. "Should the Dermatological Assessment of Patients with Inflammatory Bowel Disease Become Standard during Qualifications for Biological Treatment? A Retrospective, Single-Center Experience from a Tertiary Center" Journal of Clinical Medicine 13, no. 17: 5213. https://doi.org/10.3390/jcm13175213